




IFW

	TRANSMITTAL FORM		Application Number	10/672,429
			Filing Date	September 26, 2003
			First Named Inventor	Dempcy, Robert O.
			Art Unit	1623
			Examiner Name	Not yet assigned
Total Number of Pages in This Submission		5	Attorney Docket Number	17682A-003650US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Reference No. B13 Copy of Written Opinion
<input type="checkbox"/> Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Joseph R. Snyder		
Date	March 10, 2005	Reg. No.	39,381

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Marta R. Vanegas	Date	March 11, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 17682A-003650US
Client Reference No.: 152C1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On March 11, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Marta Vanegas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DEMPCY et al.

Application No.: 10/672,429

Filed: September 26, 2003

For: TM LEVELING METHODS

Examiner: Not yet assigned


Art Unit: 1623

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the U.S. Patent references (Ref. Nos. A1-A4) are not enclosed. In accordance with 37 CFR §1.98(d), copies of Reference Nos. B5-B12 and C14-C24 can be found in Application No. 09/796,988, filed February 28, 2001 (Attorney Docket No. 17682A-003620US). However, a copy of Reference No. B13 (Schütz et al.) is enclosed herewith for the Examiner's review.



It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "J. R. Snyder".

Joseph R. Snyder
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
JS:mr
60440755 v1



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/672,429		
		Filing Date	September 26, 2003		
		First Named Inventor	Dempcy, Robert O.		
		Art Unit	1623		
		Examiner Name	Not yet assigned		
Sheet	1	of	2	Attorney Docket Number	17682A-003650US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	A1	US-5,594,121	01-1997	Froehler et al.	
	A2	US-5,849,482	12-1998	Meyer et al.	
	A3	US-6,339,147	01-2002	Lukhtanov et al.	
	A4	US-10/302,607	n/a	Petrie et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Number ⁴					
		Country Code ³	Kind Code ⁵ (if known)				
	B5	WO	84/03285	08-30-1984	Molecular Biosystems		<input type="checkbox"/>
	B6	WO	90/03370	05-05-1990	Microprobe Corporation		<input type="checkbox"/>
	B7	WO	97/46313	12-11-1997	Array Technologies		<input type="checkbox"/>
	B8	WO	98/49180	11-05-1998	Epoch Pharmaceuticals, Inc.		<input type="checkbox"/>
	B9	WO	99/51775	10-14-1999	Epoch Pharmaceuticals, Inc.		<input type="checkbox"/>
	B10	WO	99/51621	10-14-1999	Epoch Pharmaceuticals, Inc.		<input type="checkbox"/>
	B11	WO	00/06771	02-10-2000	Affymetrix, Inc.		<input type="checkbox"/>
	B12	WO	02/12263	02-14-2002	Roche Diagnostics		<input type="checkbox"/>
	B13	EP	1103910	A1	Schütz et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60440755 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/672,429
		Filing Date	September 26, 2003
		First Named Inventor	Dempcy, Robert O.
		Art Unit	1623
		Examiner Name	Not yet assigned
		Attorney Docket Number	17682A-003650US
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C14	CLERCQ, E.D. et al. "Nucleic Acid Related Compounds. 40. Synthesis and Biological Activities of 5-Alkynyluracil Nucleosides," <i>J. Med. Chem.</i> , Vol. 26, No. 5:661-666 (1983)	
	C15	CRUICKSHANK, K.A. et al. "Oligonucleotide Labelling: A Concise Synthesis Of A Modified Thymidine Phosphoramidite," <i>Tetrahedron Letters</i> , Vol. 29 No. 41, pp 5221-5224 (1988)	
	C16	GRAHAM, D. et al. "DNA duplexes stabilized by modified monomer residues: synthesis and stability," <i>J. Chem. Soc., Perkin Trans.</i> , 1:1131-1138 (1998)	
	C17	HOBBS, F. W., Jr. "Palladium-Catalyzed Synthesis of Alkynylamino Nucleosides. A Universal Linker for Nucleic Acids," <i>J. Org. Chem.</i> , 54:3420-3422 (1989)	
	C18	ROBINS, M.J. et al. "Nucleic Acid Related Compounds. 39. Efficient Conversion of 5-Iodo to 5-Alkynyl and Derived 5-Substituted Uracil Bases and Nucleosides," <i>J. Org. Chem.</i> , 48:1854-1862 (1983)	
	C19	SEELA, F. et al. "131. 8-Aza-7-deaza-2'-deoxyguanosine: Phosphoramidite Synthesis and Properties of Octanucleotides," <i>Helvetica Chimica Acta</i> , Vol. 71:1191-1197 (1988)	
	C20	SEELA, F. et al. "8-AZA-7-Deazapurine DNA: Synthesis And Duplex Stability Of Oligonucleotides Containing 7-Substituted Bases," <i>Nucleosides & Nucleotides</i> , 18(6&7):1399-1400 (1999)	
	C21	SEELA, F. et al. "Duplex Stability Of Oligonucleotides Containing 7-Substituted 7-DEAZA- AND 8-AZA-7-Deazapurine Nucleosides," <i>Nucleosides & Nucleotides</i> , 16(7-9):963-966 (1997)	
	C22	SEELA, F. et al. "Oligonucleotides Containing Pyrazolo [3,4-d] pyrimidines: The Influence of 7-Substituted 8-Aza-7-deaza-2'-deoxyguanosines on the Duplex Structure and Stability," <i>Helvetica Chimica Acta</i> , Vol. 82:1640-1655 (1999)	
	C23	SEELA, F. et al. "Synthesis of 7-alkynylated 8-aza-7-deaza-2'-deoxyadenosines via the Pd-catalysed cross-coupling reaction," <i>J. Chem. Soc., Perkin Trans.</i> , 1:3233-3239 (1998)	
	C24	SEELA, F. et al. "The Influence of Modified Purine Bases on the Stability of Parallel DNA," <i>Bioorganic & Medicinal Chemistry Letters</i> , 10:289-292 (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.